About US
Contact us
-
GlaxoSmithKline faces new allegations over China Botox salesGlaxoSmithKline ($GSK) is again scrambling to put out fires, asThe Wall Street Journalhas published new allegations suggesting that GSK employees paid Chinese doctors bribes to prescribe drugs,Botoxin2013/7/9
-
Lilly's Lechleiter returns to CEO suite after surgeryEli Lilly ($LLY) CEOJohn Lechleiteris back on the job. Two months ago, Lechleiter bowed out for surgery on a dilated aorta, handing over the reins to CFODerica Rice. Now, the company says he has the g2013/7/9
-
Roche bids for broad use of HPV test to screen for cervical cancerRoche ($RHHBY) is aiming to make itshuman papillomavirustest a first-line diagnostic forcervical cancer, with a new FDA application for the Cobas HPV as a substitute for Pap tests. Currently the test2013/7/8
-
China taking closer look at drug prices, cost structureChinese regulators say they will size up the cost structures and pricing of 60 drugmakers, both domestic and foreign, as it figures out what it should be paying for drugs. According toBloomberg, the N2013/7/8
-
Fresenius gets warning letter for India plantFreseniusKabi, the generic drug unit for the German healthcare company, this week received an FDA warning letter for a plant in India. The company said it is dealing with the issues, but its work on t2013/7/8
-
CFDA Vice Minister Liu Peizhi meets the French Foreign Minister's Special Representative for China Affairs and French Ambassador to ChinaOn the morning of July 2, 2013, Liu Peizhi, Vice Minister of China Food and Drug Administration (CFDA) met with the delegation led by Martine Aubry, the French Foreign Minister's Special Representativ2013/7/4
-
CFDA Assistant Minister Bian Zhenjia meets Deputy Minister of Health of VietnamOn June 25, 2013, Bian Zhenjia, Assistant Minister of China Food and Drug Administration (CFDA), met with the delegation led by Mr. Pham Le Tuan, Deputy Minister of Health of Vietnam, and introduced t2013/7/4
-
Sanofi shaves 207 R&D jobs in scaled-back reorgUnder assault from union leaders and government officials, Sanofi ($SNY) was forced to back off plans to engineer a major reorganization of its R&D operations in France. But it's going ahead with2013/7/4
-
Indian drugmakers balk at new Actos banIndian drugmakers are fighting the country's new ban on thediabetes drugpioglitazone, otherwise known asActos. Regulators suspended sales of the drug last week, citing safety worries, including concer2013/7/4
-
Is GlaxoSmithKline's China probe a harbinger of more?Are more drugmakers at risk of corruption probes inChina? After GlaxoSmithKline employees were detained in an investigation of "economic crimes," industry watchers point out that the Chinese governmen2013/7/3